

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	HeraMED Limited
ABN	65 626 295 314

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Tal Slonim
Date of last notice	11 December 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Altshuler Shaham Trusts Ltd <Tal Slonim A/C> (beneficial holder)
Date of change	28 November 2019
No. of securities held prior to change	7,995,723 Ordinary fully paid ordinary shares escrowed 24 months from quotation 3,187,500 Unlisted options @ \$0.25 expiring 5/12/21 escrowed 24 months from quotation 463,752 Unlisted options @ \$0.00002 expiring 5/12/21 escrowed 24 months from quotation
Class	Ordinary fully paid ordinary shares escrowed 24 months from quotation
Number acquired	1,249,695

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Deferred Consideration Shares issued to the vendors (and/or their nominees) as part of the Acquisition – refer Section 7.1(b)(ii) of the Prospectus dated 15/10/18. The securities have been issued upon meeting the performance milestone being receipt of the FDA approval, which was announced on 18/11/19.
No. of securities held after change	9,245,418 Ordinary fully paid ordinary shares escrowed 24 months from quotation 3,187,500 Unlisted options @ \$0.25 expiring 5/12/21 escrowed 24 months from quotation 463,752 Unlisted options @ \$0.00002 expiring 5/12/21 escrowed 24 months from quotation
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Deferred Consideration Shares issued to the vendors (and/or their nominees) as part of the Acquisition – refer Section 7.1(b)(ii) of the Prospectus dated 15/10/18. The securities have been issued upon meeting the performance milestone being receipt of the FDA approval, which was announced on 18/11/19.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.